Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma
Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Alexandra Drakaki, MD, PhD, assistant professor of medicine, hematology, and oncology, and medical director of Genitourinary Oncology Program, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
The aim of the trial is to identify an optimal combination that will enhance the immune system, as well as elicit tumor infiltration and immune cell activation, Drakaki explains. Researchers are interested in determining the mechanisms of resistance, and how future combinations can be modified for patients. The benefit of this trial is that arms that are not showing efficacy will be closed, and new arms will open to evaluate their efficacy, she adds.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
